BioRender has raised not fully disclosed across 1 funding round, plus 1 undated round. The latest round valued BioRender at $900M post-money, with Dimension Capital on the lead line.
BioRender says it is profitable and backed by top investors, and Y Combinator partner Garry Tan says he led the company's Series A round after seeing its growth metrics firsthand.
1 funding round, the latest highlighted.
BioRender was founded in 2017, Canada.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. Led by Dimension Capital.
No filing has been made.
1 dated round, newest first.
Y CombinatorThe closest scientific visualization software peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. BioRender is a private company; its shares do not trade on a public exchange.
The last valuation is $900M (post-money, Dec 2025).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
